Recent gene expression analysis identified CXCL10 as one of the five candidate therapeutic targets for the treatment of NAFLD, highlighting its role in NAFLD progression [34]. This evidence concerns the gene CXCL10 and metabolic dysfunction-associated steatotic liver disease.